Myovant Sciences Ltd.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David C. Marek
- Full Time Employees
- 579
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11-12 St. James’s Square London United Kingdom SW1Y 4LB
- IPO Date
- Oct 27, 2016
- CIK
- 0001679082
- Website
- myovant.com
- Similar Companies
- Business
- Myovant Sciences Ltd. (MYOV) is a biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine disorders, including advanced prostate cancer; its lead product, relugolix, is an oral, once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist marketed as ORGOVYX for adult patients with advanced prostate cancer and as MYFEMBREE, a relugolix combination tablet, for the management of heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis. The company also advances MVT-602, an oligopeptide kisspeptin agonist in Phase II clinical trials for female infertility as part of assisted reproduction, and through its subsidiary Myovant Sciences GmbH, pursues supplemental New Drug Applications for MYFEMBREE in additional endometriosis indications and contraceptive efficacy. Myovant Sciences Ltd., founded in 2016 and headquartered in Brisbane, California, with key operations in Basel, Switzerland, conducts global development and commercialization activities across the United States, Europe, and select international markets, targeting patients in women's health, urology, and oncology segments. In recent developments, Sumitovant Biopharma Ltd., a subsidiary of Sumitomo Pharma Co. Ltd., completed its acquisition of all outstanding shares of Myovant Sciences in an all-cash transaction valued at approximately $1.7 billion in early 2023, leading to Myovant's delisting from the New York Stock Exchange and integration into Sumitomo Pharma America as of July 2023, while Myovant Sciences GmbH operates as Sumitomo Pharma Switzerland. Myovant entered an exclusive license agreement with Accord Healthcare Ltd. in 2025 for commercialization of relugolix in Europe, entitling Myovant to an upfront payment of $50 million and up to $90.5 million in milestones, with Accord handling local development and sales in specified territories. Earlier collaborations include a partnership with Pfizer Inc. for relugolix development and commercialization in oncology and women's health, alongside ongoing European Commission approvals for ORGOVYX and RYEQO in advanced hormone-sensitive prostate cancer and uterine fibroids.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
SHAREHOLDER ALERT: Weiss Law Reminds MYOV, KNBE, LMST, and PEBO Shareholders About Its Ongoing Investigations
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
Why Sumitomo Pharma Is Buying Myovant Sciences (MYOV) For $2.9 Billion
Myovant Sciences Cancels Second Quarter Earnings Conference Call
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
Why Myovant Sciences Stock Is Moving Higher - Myovant Sciences (NYSE:MYOV)
Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
Myovant Sciences: What The Sumitomo Offer Foretells
Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?
Why Myovant Sciences Stock Is Skyrocketing Today
Myovant stock opened 35% up on Monday: here's the catalyst
Myovant Sciences Stock Skyrockets After Rejecting Buyout Offer